Arrowhead Pharma (ARWR)

$60.67 +0.85 (1.42%)
Market Cap 8.38B
Revenue (ttm) 829.45M
Net Income (ttm) -1.63M
EPS (ttm) N/A
PE Ratio 41.57
Forward PE N/A
Profit Margin -0.20%
Debt to Equity Ratio 0.36
Volume 2,217,352
Avg Vol 2,865,934
Day's Range N/A - N/A
Shares Out 140.03M
Stochastic %K 25%
Beta 1.23
Analysts Strong Sell
Price Target $81.67

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, t...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
Steppinstone
Steppinstone Mar. 9 at 2:23 PM
$ARWR There are a few solid winners but otherwise just a sea of red in biotechland today. Just a reminder that trouble in the Strait of Hormuz and volatile oil prices can rattle global markets.
1 · Reply
skeezbag
skeezbag Mar. 9 at 2:05 PM
$ARWR who is ready for the new fake ceiling of 58 Go fuck yourselves shareholders! Cc market maker and supply demand team
0 · Reply
BiodegradableBurger
BiodegradableBurger Mar. 9 at 12:45 PM
$ARWR Is Israel bombing our FCS patients?
0 · Reply
skeezbag
skeezbag Mar. 9 at 12:02 PM
$ARWR guess all the oil fields arrowhead owns are worthless
0 · Reply
HokieStock
HokieStock Mar. 8 at 3:52 AM
$ARWR Takeda completed and checked in on the Alpha 1 anti-trypsin product last week. Would be nice for them to come out with more guidance. That trial looking at other liver disease and possible benefits could be very interesting. Remember you only need one phase 3 moving forward so that should be very beneficial for HSD in multiple possible indications and others thinking.
1 · Reply
aga5757st
aga5757st Mar. 6 at 8:36 PM
$ARWR Besides, all the factors discussed, FDA mix messaging in approval negotiations; spotty volume; whats turned into technical resistance, etc. Is there any company specific reason for this 6-8% decline?
0 · Reply
skeezbag
skeezbag Mar. 6 at 8:01 PM
$ARWR almost time shareholders. Get ready to fuck yourselves supply and demand about to happen
0 · Reply
LeftyT
LeftyT Mar. 6 at 7:12 PM
$SLS Sold half my March 20 $5 calls for 75 cents and a nice 135% profit. Letting the rest run on house money. Put my profits into another 100 sh of $ARWR on today's algo dip at 58.95. Holding all SLS shares and July $4 calls for the long haul.
2 · Reply
LeftyT
LeftyT Mar. 6 at 7:07 PM
$ARWR Added another 100 sh at 58.95. F_ck the machines!!!!
0 · Reply
skeezbag
skeezbag Mar. 6 at 6:48 PM
$ARWR found fake vwap for today. Get your Ulz and leerink but lube ready for the afternoon tank Same daily repeatable pattern different day Fun fact supply does not equal demand
0 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Feb 24, 2026, 7:30 AM EST - 13 days ago

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript

Feb 6, 2026, 12:34 AM EST - 4 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Feb 5, 2026, 4:05 PM EST - 4 weeks ago

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Feb 4, 2026, 6:15 PM EST - 4 weeks ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT CIEN DAY DVAX OSW

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Jan 27, 2026, 7:30 AM EST - 5 weeks ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Jan 20, 2026, 4:30 PM EST - 6 weeks ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 2:06 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Jan 7, 2026, 11:05 PM EST - 2 months ago

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Jan 7, 2026, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Jan 6, 2026, 6:14 PM EST - 2 months ago

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Jan 6, 2026, 3:18 PM EST - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 6, 2026, 2:58 PM EST - 2 months ago

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Jan 6, 2026, 11:26 AM EST - 2 months ago

Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay.

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Jan 6, 2026, 10:32 AM EST - 2 months ago

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Jan 6, 2026, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Jan 5, 2026, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Dec 23, 2025, 7:30 AM EST - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Dec 15, 2025, 4:30 PM EST - 2 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Dec 8, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Dec 2, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Dec 1, 2025, 4:00 PM EST - 3 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Nov 27, 2025, 7:43 PM EST - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 11:43 PM EST - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Nov 25, 2025, 4:00 PM EST - 3 months ago

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

Nov 24, 2025, 7:30 AM EST - 3 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Nov 19, 2025, 3:48 AM EST - 3 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Nov 18, 2025, 11:54 PM EST - 3 months ago

Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Nov 18, 2025, 11:52 AM EST - 3 months ago

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

US FDA approves Arrowhead's genetic disorder drug

Nov 18, 2025, 11:21 AM EST - 3 months ago

US FDA approves Arrowhead's genetic disorder drug

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Nov 17, 2025, 10:08 AM EST - 4 months ago

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Nov 6, 2025, 4:30 PM EST - 4 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Nov 4, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 21, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 5 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 11, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:55 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 10, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:42 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:35 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Sep 3, 2025, 4:00 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Sep 3, 2025, 1:15 PM EDT - 6 months ago

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025, 8:13 AM EDT - 6 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Sep 2, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 7 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 8, 2025, 8:48 PM EDT - 7 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 7 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Steppinstone
Steppinstone Mar. 9 at 2:23 PM
$ARWR There are a few solid winners but otherwise just a sea of red in biotechland today. Just a reminder that trouble in the Strait of Hormuz and volatile oil prices can rattle global markets.
1 · Reply
skeezbag
skeezbag Mar. 9 at 2:05 PM
$ARWR who is ready for the new fake ceiling of 58 Go fuck yourselves shareholders! Cc market maker and supply demand team
0 · Reply
BiodegradableBurger
BiodegradableBurger Mar. 9 at 12:45 PM
$ARWR Is Israel bombing our FCS patients?
0 · Reply
skeezbag
skeezbag Mar. 9 at 12:02 PM
$ARWR guess all the oil fields arrowhead owns are worthless
0 · Reply
HokieStock
HokieStock Mar. 8 at 3:52 AM
$ARWR Takeda completed and checked in on the Alpha 1 anti-trypsin product last week. Would be nice for them to come out with more guidance. That trial looking at other liver disease and possible benefits could be very interesting. Remember you only need one phase 3 moving forward so that should be very beneficial for HSD in multiple possible indications and others thinking.
1 · Reply
aga5757st
aga5757st Mar. 6 at 8:36 PM
$ARWR Besides, all the factors discussed, FDA mix messaging in approval negotiations; spotty volume; whats turned into technical resistance, etc. Is there any company specific reason for this 6-8% decline?
0 · Reply
skeezbag
skeezbag Mar. 6 at 8:01 PM
$ARWR almost time shareholders. Get ready to fuck yourselves supply and demand about to happen
0 · Reply
LeftyT
LeftyT Mar. 6 at 7:12 PM
$SLS Sold half my March 20 $5 calls for 75 cents and a nice 135% profit. Letting the rest run on house money. Put my profits into another 100 sh of $ARWR on today's algo dip at 58.95. Holding all SLS shares and July $4 calls for the long haul.
2 · Reply
LeftyT
LeftyT Mar. 6 at 7:07 PM
$ARWR Added another 100 sh at 58.95. F_ck the machines!!!!
0 · Reply
skeezbag
skeezbag Mar. 6 at 6:48 PM
$ARWR found fake vwap for today. Get your Ulz and leerink but lube ready for the afternoon tank Same daily repeatable pattern different day Fun fact supply does not equal demand
0 · Reply
skeezbag
skeezbag Mar. 6 at 6:13 PM
$ARWR enjoy the intraday daily fake rally Gotta make the chart look like shit to keep buyers away once again #itsnotsupplyanddemanddumbass
0 · Reply
negateski23
negateski23 Mar. 6 at 5:53 PM
$ARWR anyone have a quote on converts?
0 · Reply
HokieStock
HokieStock Mar. 6 at 5:51 PM
$ARWR This is chart related and has been on there for awhile, if you have not started a position a good place to enter. Anticipate HEP-B news, GSK HSD and Amgen as well over the next couple months to end of year. Dimer is much more advanced than we thought and that news and others are very close. Found it very interesting about other dimers by the end of the year. There is still alot that is not being discussed. Do wish complement franchise someone would pick up because those drugs makes sense as long term dosing and benefits. That gap 44 to 57 to 63 has been there for awhile but the 70 dollar 40 was a similiar trend in 2021. But this company really is worth x now. Keep some dry powder but also do not be afraid to enter here as well.
1 · Reply
DoctorJT
DoctorJT Mar. 6 at 5:45 PM
$ARWR are they gonna drop bad news about one of the indications after the bell?
0 · Reply
Synaptric
Synaptric Mar. 6 at 5:38 PM
$ARWR "On business development, Anzalone said Arrowhead does not need additional near-term partnerships and listed multiple core programs as “off the table” for partnering at present. He said the company is looking to out-license certain assets it does not plan to commercialize, including ARO-PNPLA3, as well as complement programs targeting C3 and factor B." I interpret this as: since we had a successful cash raise this past January, we dontneednobodyelse. https://www.marketbeat.com/instant-alerts/arrowhead-pharmaceuticals-teases-2026-catalysts-waylivra-launch-momentum-at-td-cowen-conference-2026-03-04/
0 · Reply
Jschwarma
Jschwarma Mar. 6 at 5:26 PM
$ARWR sick $ raise at 64 last month
0 · Reply
Jschwarma
Jschwarma Mar. 6 at 4:46 PM
$ARWR Every month without news allows for tutes to protect their OTM calls
0 · Reply
putsandcalls
putsandcalls Mar. 6 at 4:36 PM
$ARWR rat die in lab?
0 · Reply
Gabriel_DS
Gabriel_DS Mar. 6 at 4:22 PM
$ARWR any reason for the drop?
2 · Reply
Steppinstone
Steppinstone Mar. 6 at 4:03 PM
$ARWR Adding more today. Bond coupon $$$ arrived at a timely moment.
0 · Reply
negateski23
negateski23 Mar. 6 at 4:01 PM
$ARWR I don't think anyone cares about this name on days like today, weeks like this week. Prob 3 people trading it.
0 · Reply
Jschwarma
Jschwarma Mar. 6 at 3:52 PM
$ARWR this is so fkn obvious. nice call by james getting $64 for his. Could buy back for 15% cheaper today if he wanted
1 · Reply